MedTrace Logo

Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma

NCT04535271 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-02-24

No results posted yet for this study

Summary

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Conditions

  • Leiomyosarcoma

Interventions

DRUG

Trabectedin

This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.

Sponsors & Collaborators

  • Sarcoma Oncology Research Center, LLC

    lead OTHER

Principal Investigators

  • Sant P Chawla, MD · Sarcoma Oncology Research Center, LLC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-09
Primary Completion
2028-09-30
Completion
2029-03-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04535271 on ClinicalTrials.gov